Predictive Value of Circulating microRNA-134 Levels for Early Diagnosis of Acute Pulmonary Embolism: Meta-analysis

Liu, Yu; Xie, Ming; Gao, Xiaoli; Liu, Ran

doi:10.1007/s12265-020-10087-4

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For miR-134, a meta-analysis also reported that its level was increased in APE patients compared to that in the control group (SMD = 2.84, z = 3.69, p < 0.001). The sensitivity, specificity, and diagnostic odds ratio were 0.86 (0.72–0.94), 0.75 (0.66–0.82), and 19 (7–51) respectively, which indicated its great potential as a PE biomarker ( Liu et al, 2021 ). Among the variety of miRNA-related PE studies, research on miR-134 is the most extensive and reliable up to date ( Xiao et al, 2011 ; Xiang et al, 2019 ).…”

Section: Mirnas As Pe Biomarkersmentioning

confidence: 98%

The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook

Luo

Shu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Pulmonary embolism (PE) is a common pathologic condition that frequently occurs in patients with deep venous thrombosis. Severe PE may critically suppress cardiopulmonary function, thereby threatening the life of patients. Chronic pulmonary hypertension caused by PE may lead to deterioration of respiratory dysfunction, resulting in complete disability. MicroRNAs (miRNAs) are a group of abundantly expressed non-coding RNAs that exert multiple functions in regulating the transcriptome via post-transcriptional targeting of mRNAs. Specifically, miRNAs bind to target mRNAs in a matching mechanism between the miRNA seed sequence and mRNA 3ʹ UTR, thus modulating the transcript stability or subsequent translation activity by RNA-induced silencing complex. Current studies have reported the function of miRNAs as biomarkers of PE, revealing their mechanism, function, and targetome in venous thrombophilia. This review summarizes the literature on miRNA functions and downstream mechanisms in PE. We conclude that various related miRNAs play important roles in PE and have great potential as treatment targets. For clinical application, we propose that miRNA biomarkers combined with traditional biomarkers or miRNA signatures generated from microchips may serve as a great predictive tool for PE occurrence and prognosis. Further, therapies targeting miRNAs or their upstream/downstream molecules need to be developed more quickly to keep up with the progress of routine treatments, such as anticoagulation, thrombolysis, or surgery.

show abstract

Section: Mirnas As Pe Biomarkersmentioning

confidence: 98%

The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook

Luo

Shu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…57 Recent experiments show that the level of microRNA-134 in the plasma of patients with PE is significantly higher than that of non-PE patients. 58 Circulating miR-28-3p was identified to predict the diagnosis of APE in plasma of APE patents. 59 Latest data identified circulating miR-1233 as a sensitive and specific biomarker for the early diagnosis of APE.…”

Section: Micrornasmentioning

confidence: 99%

Research progress on biomarkers of pulmonary embolism

Yang

Zhang

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

Objectives: To present a review on the traditional and new biomarkers of pulmonary embolism (PE). Data source: A systematic search has been carried out using keywords as PE, biomarker, diagnosis and risk stratification. Results: The results of this work have been structured into three parts: first, conventional biomarkers for vascular, cardiac and inflammation, including static markers and dynamic markers for measuring the time course; next, a review of new biomarkers in recent years, such as RNAs and markers obtained through proteomics and mass spectrometry; finally, use of new detection methods to directly detect the activity of existing markers, such as the determination of coagulation factor II and plasmin activities based on the proteolytic activation of an engineered zymogen. Conclusions: This work summarized the characteristics of current traditional biomarkers for clinical diagnosis and risk stratification of PE, as well as a series of newly discovered biomarkers obtained through various clinical experimental methods.

show abstract

“…As part of the clinical diagnosis, deep vein thrombosis (DVT) is a major clinical manifestation of venous thromboembolism and pulmonary thromboembolism (PTE) is a major complication of DVT (3 5). DVT and PTE are important causes of morbidity and mortality; therefore, early diagnosis is needed to treat patients more effectively and to reduce mortality (6,7).…”

Section: Introductionmentioning

confidence: 99%

Clinical value of deep vein thrombosis density on pre-contrast and post-contrast lower-extremity CT for prediction of pulmonary thromboembolism

et al. 2022

View full text Add to dashboard Cite

Background There was a lack of studies assessing the relationship between deep vein thrombosis (DVT) Hounsfield unit (HU) density and pulmonary thromboembolism (PTE). Purpose To evaluate the clinical value of DVT density measured on pre- and post-contrast lower-extremity computed tomography (CT) for the prediction of PTE. Material and Methods From 2017 to 2021, patients who underwent pulmonary CT angiography within one week after diagnosis of DVT on lower-extremity CT were included in this retrospective study. Then, the patients without PTE were included in “DVT group” and those with both DVT and PTE were included in the “DVT-PTE group.” The DVT HU density was measured by drawing free-hand region of interests (ROIs) within the thrombus at the most proximal filling defect level. A receiver operating characteristic (ROC) analysis was used to evaluate the predictive value of DVT density for the risk of PTE. Results This study included a total of 94 patients (DVT group: n=56; DVT-PTE group: m=38). DVT density was significantly higher in the DVT-PTE group than the DVT group in both pre-contrast (53.5 ± 6.2 HU vs. 44.1 ± 7.9 HU; P < 0.001) and post-contrast CT (67.0 ± 8.6 HU vs. 57.1 ± 10.6 HU; P < 0.001). ROC analysis revealed that the area under curve, sensitivity, and specificity for predicting the risk of PTE were 0.739, 71.1%, and 64.2%, respectively, at a DVT density cutoff of 48.2 HU on pre-contrast CT and were 0.779, 73.7%, and 69.6% at a DVT density cutoff of 61.8 HU on post-contrast CT. Conclusion The DVT density on both pre- and post-contrast CT could be a predictive factor of PTE.

show abstract

Predictive Value of Circulating microRNA-134 Levels for Early Diagnosis of Acute Pulmonary Embolism: Meta-analysis

Cited by 6 publications

References 26 publications

The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook

The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook

Research progress on biomarkers of pulmonary embolism

Clinical value of deep vein thrombosis density on pre-contrast and post-contrast lower-extremity CT for prediction of pulmonary thromboembolism

Contact Info

Product

Resources

About